Morningstar

Insmed Inc INSM

Stock XNAS Rating as of Oct 2, 2026

News

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

PR Newswire Sep 21, 2026, 11:00:00 AM
Insmed Expands Community Impact During Fifth Annual Global Day of Good

PR Newswire Sep 16, 2026, 11:00:00 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire Sep 4, 2026, 11:00:00 AM
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026

PR Newswire Sep 3, 2026, 11:00:00 AM
Insmed to Present at September 2026 Investor Conferences

PR Newswire Aug 26, 2026, 11:00:00 AM
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

PR Newswire Aug 24, 2026, 11:00:00 AM
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

PR Newswire Aug 6, 2026, 11:00:00 AM
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

PR Newswire Jul 23, 2026, 11:00:00 AM
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension

PR Newswire Jul 16, 2026, 11:00:00 AM
Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

Global News Select Dec 17, 2025, 11:50:00 PM
Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut

MarketWatch Dec 13, 2025, 4:04:00 PM
These 15 stocks are still showing momentum - and a market-beating edge

MarketWatch Nov 20, 2025, 11:06:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.